肠菌移植治疗炎症性肠病14例临床观察

Clinical observation on 14 cases of inflammatory bowel disease treated by fecal microbiota transplantation

目的:观察肠菌移植治疗炎症性肠病的安全性和有效性,评价对治疗后炎症指标、疾病评分及肠道菌群组成的影响。方法:选取2018年12月至2021年12月于医院肛肠科行肠菌移植治疗炎症性肠病的14例患者,比较治疗前后患者炎症指标、疾病评分及治疗效果,16s rDNA检测肠道菌群变化。结果:经肠菌移植后,第15周临床有效率为85.71%(13/15);患者炎症指标、Mayo及疾病评分、肠道菌群多样性及相对丰度较前改善,差异具有统计学意义(P<0.05)。结论:肠菌移植治疗炎症性肠病疗效显著,不良反应少,安全性高,值得临床推广应用。

Objective:To observe the safety and efficacy of fecal microbiota transplantation in the treatment of inflammatory bowel dis⁃ease,and to evaluate the effect on inflammatory indexes,disease scores,and composition of gut microbiota after treatment.Methods:A total of 14 patients with inflammatory bowel disease who underwent fecal microbiota transplantation in the Anorectal Department of our hospital from December 2018 to December 2021 were selected to compare the clinical efficacy,inflammatory indexes,Mayo and CDAI disease scores,and to compare the composition of gut microbiota by 16s rDNA detection before and after treatment.Results:After fecal microbiota transplantation,the clinical remission rate was 85.71%(13/15)in the 15th week;the inflammatory indexes,Mayo and CDAI disease scores,diversity and relative abundance of gut microbiota were improved,and the differences were statistically significant(P<0.05).Conclusion:Fecal microbiota transplantation in the treatment of inflammatory bowel disease has a significant curative effect,few adverse reactions,and high safety,which is worthy of clinical application.